Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
28.31
+0.51 (1.83%)
Sep 4, 2025, 3:30 PM - Market open
Apellis Pharmaceuticals Stock Forecast
Stock Price Forecast
The 19 analysts that cover Apellis Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $34.11, which forecasts a 20.49% increase in the stock price over the next year. The lowest target is $18 and the highest is $57.
Price Target: $34.11 (+20.49%)
Analyst Consensus: Buy
* Price targets were last updated on Aug 4, 2025.
Analyst Ratings
The average analyst rating for Apellis Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 4 | 4 | 4 | 3 |
| Buy | 4 | 5 | 6 | 6 | 6 | 7 |
| Hold | 8 | 8 | 9 | 9 | 9 | 10 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 18 | 18 | 19 | 19 | 19 | 20 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $35 → $37 | Buy | Maintains | $35 → $37 | +30.70% | Aug 4, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $46 → $52 | Strong Buy | Maintains | $46 → $52 | +83.68% | Aug 1, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $17 → $19 | Hold | Maintains | $17 → $19 | -32.89% | Aug 1, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $39 → $40 | Buy | Maintains | $39 → $40 | +41.29% | Aug 1, 2025 |
| Raymond James | Raymond James | Buy Maintains $52 → $50 | Buy | Maintains | $52 → $50 | +76.62% | Aug 1, 2025 |
Financial Forecast
Revenue This Year
942.23M
from 781.37M
Increased by 20.59%
Revenue Next Year
922.96M
from 942.23M
Decreased by -2.05%
EPS This Year
-0.79
from -1.60
EPS Next Year
-0.93
from -0.79
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.1B | 1.1B | |||
| Avg | 942.2M | 923.0M | |||
| Low | 691.3M | 742.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 40.0% | 14.2% | |||
| Avg | 20.6% | -2.0% | |||
| Low | -11.5% | -21.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.41 | 1.78 | |||
| Avg | -0.79 | -0.93 | |||
| Low | -2.24 | -2.20 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.